Neurocrine Biosciences Inc NBIX

Neurocrine Biosciences, Inc. es una empresa biofarmacéutica centrada en neurociencia. La empresa se enfoca en descubrir, desarrollar y comercializar productos farmacéuticos para el tratamiento de enfermedades y trastornos neurológicos, endocrinos y psiquiátricos. Su cartera incluye tratamientos para la discinesia tardía, la enfermedad de Parkinson, la endometriosis y los fibromas uterinos. Su línea de productos incluye INGREZZA (valbenazina), que ofrece una opción de tratamiento de dosificación diaria para la discinesia tardía y tiene tres opciones de dosificación (cápsulas de 40 miligramos (mg), 60 mg y 80 mg); ONGENTYS (opicapona) es una terapia adyuvante a levodopa/carbidopa en pacientes con enfermedad de Parkinson; ORILISSA (elagolix) se utiliza para el manejo del dolor moderado a severo de la endometriosis en mujeres, y ORIAHNN (cápsulas de elagolix, estradiol y acetato de noretindrona y elagolix) es una opción de medicación oral no quirúrgica para el manejo de sangrado menstrual abundante asociado con fibromas uterinos en mujeres.

• GlobeNewswire Inc. 26 ago

  Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition

  Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567, an oral muscarinic M1/M4 selective agonist for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment. This marks the third compound in Nxera's muscarinic agonist portfolio to advance to Phase 2, following direclidine in Phase 3 and NBI-1117570 in Phase 2.

  

• GlobeNewswire Inc. 7 ago

  Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026

  Nxera Pharma reported strong Q2 2026 results with revenue of JPY 18.9 billion, up from the prior year, driven by eight R&D milestone events. The company achieved key regulatory designations for vamorolone in South Korea, progressed partnered programs with Neurocrine, Lilly, and AbbVie, and benefited from Lilly's acquisition of Centessa Pharmaceuticals. Operating profit turned positive at JPY 1.9 billion versus a prior loss, with core operating profit reaching JPY 6.5 billion.

  

• Benzinga 10 jun

  Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys

  Fundstrat Capital completed its May 2026 quarterly rebalance of the Fundstrat Granny Shots US Small- & Mid-Cap ETF (GRNJ), adding 10 stocks including First Solar, Zoom, Credo Technology, and Neurocrine Biosciences, while removing 8 positions. CIO Tom Lee positions the portfolio for a 'challenging but ultimately constructive' environment, with the strategy focusing on companies benefiting from structural tailwinds across themes like Millennials, Global Labor Supply, Energy, Cybersecurity, and Easing Financial Conditions.